Additionally, the 36-month beta value for TNDM is 1.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for TNDM is 64.13M and currently, short sellers hold a 14.52% ratio of that float. The average trading volume of TNDM on April 17, 2024 was 1.80M shares.
TNDM) stock’s latest price update
Tandem Diabetes Care Inc (NASDAQ: TNDM) has experienced a rise in its stock price by 3.45 compared to its previous closing price of 31.86. However, the company has seen a fall of -5.53% in its stock price over the last five trading days. Business Wire reported 2024-04-09 that SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes.
TNDM’s Market Performance
Tandem Diabetes Care Inc (TNDM) has experienced a -5.53% fall in stock performance for the past week, with a 15.16% rise in the past month, and a 29.20% rise in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 5.71% for TNDM. The simple moving average for the last 20 days is -0.37% for TNDM’s stock, with a simple moving average of 29.45% for the last 200 days.
Analysts’ Opinion of TNDM
Many brokerage firms have already submitted their reports for TNDM stocks, with Stifel repeating the rating for TNDM by listing it as a “Buy.” The predicted price for TNDM in the upcoming period, according to Stifel is $37 based on the research report published on March 26, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see TNDM reach a price target of $33, previously predicting the price at $45. The rating they have provided for TNDM stocks is “Neutral” according to the report published on August 04th, 2023.
BofA Securities gave a rating of “Underperform” to TNDM, setting the target price at $33 in the report published on May 05th of the previous year.
TNDM Trading at 13.56% from the 50-Day Moving Average
After a stumble in the market that brought TNDM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.69% of loss for the given period.
Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares surge +5.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.95% upper at present.
During the last 5 trading sessions, TNDM fell by -5.53%, which changed the moving average for the period of 200-days by +29.05% in comparison to the 20-day moving average, which settled at $33.18. In addition, Tandem Diabetes Care Inc saw 11.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNDM starting from Allen Dick, who purchase 5,000 shares at the price of $18.96 back on Nov 27 ’23. After this action, Allen Dick now owns 19,962 shares of Tandem Diabetes Care Inc, valued at $94,778 using the latest closing price.
Vosseller Leigh, the EVP & CHIEF FINANCIAL OFFICER of Tandem Diabetes Care Inc, purchase 6,200 shares at $15.39 during a trade that took place back on Nov 08 ’23, which means that Vosseller Leigh is holding 11,860 shares at $95,395 based on the most recent closing price.
Stock Fundamentals for TNDM
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.49 for the gross margin
The net margin for Tandem Diabetes Care Inc stands at -0.3. The total capital return value is set at -0.2. Equity return is now at value -59.08, with -22.20 for asset returns.
Based on Tandem Diabetes Care Inc (TNDM), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.08. The debt to equity ratio resting at 1.33. The interest coverage ratio of the stock is 41.36.
Currently, EBITDA for the company is -118.22 million with net debt to EBITDA at -6.29. When we switch over and look at the enterprise to sales, we see a ratio of 3.32. The receivables turnover for the company is 7.08for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.83.
Conclusion
In conclusion, Tandem Diabetes Care Inc (TNDM) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
